Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant ...

This might sound surprising, but getting diagnosed with immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura, or ITP) can come as a relief. You can figure out ITP treatment, of ...

"The treatment paradigm of ITP is slowly shifting due to expanding experience with earlier use of TPO-RAs and TPO-mimetics in chronic and refractory ITP…Most of these agents are oral and better ...

New prospective research builds on a previous study that showed guidelines aren’t the main driver of treatment selection in pediatric patients with ITP. Of 12 potential reasons for prescribing ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

Immune thrombocytopenia (ITP) is a rare condition that causes a low platelet count. People with ITP can experience life threatening bleeding if the condition is not treated. Many people with ITP go ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Immune thrombocytopenia (ITP) doesn’t have a cure and can be unpredictable. There are two main types of ITP, acute and chronic. The acute type usually lasts six months or less. It’s more common in ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first ...